KalVista Pharmaceuticals announces FDA Approval of Ekterly (sebetralstat), first and only oral on-demand treatment for hereditary angioedema

KalVista Pharmaceuticals

7 July 2025 - First new on demand hereditary angioedema treatment in over a decade, with potential to transform management of the disease.

KalVista Pharmaceuticals today announced that the US FDA has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema in adult and paediatric patients aged 12 years and older.

Read KalVista Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Registration